Nathalie Adda

Since 2015, Dr Adda has been Sr Vice President Clinical & Regulatory Affairs, and Chief Medical officer at Enanta where she has been leading Liver disease (NASH, PBC) and Viral Disease (HCV, HBV, RSV) programs.

Dr. Adda is a specialist in infectious disease and has 20 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization. From 2012 to 2015, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs. From 2006 to 2012, she was Senior Medical Director and the medical lead for the IncivekĀ® (telaprevir) Clinical Program at Vertex Pharmaceuticals Inc., where she designed the phase 2 and Phase 3 programs, and led the medical team in its successful marketing applications and registration in the USA, Canada, and, Asia. Earlier in her career, she held medical and research positions at Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where she worked on programs for infectious diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). Prior to her positions in industry she was a Clinical Research Medical Monitor employed by the ANRS (National Agency for Research on AIDS & Hepatitis) where she was in charge of a Research Unit.

Dr. Adda is a graduate of the University of Paris, where she received a Doctorate in Medicine, as well as a Masterā€™s Degree in Biostatistics, and where she did post-graduate work in infectious diseases.

She has authored/co-authored over 150 abstracts, publications, reports & training courses. She has made multiple presentations at national and international scientific meetings and was a key member of the Vertex team at the FDA Antiviral Advisory Committee meeting in April 2011.

She has also a past experience in humanitarian and philanthropic activities and has worked in Egypt (Institute of Oncology, Cairo), and Senegal (Sine Saloum, dispensaries).